bmiMD Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 9.1/10
Best for: starting below a standard dose, with microdose tiers
bmiMD's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to bmiMD
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
bmiMD at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo (Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How bmiMD scores
Six columns, each one computed from something bmiMD has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
9.7/10$139/month is 48% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on bmiMD
Last checked July 2026- Re-read the price on file across 4 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with bmiMD involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1bmiMD publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3bmiMD does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $99, tirzepatide $139. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for all 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications bmiMD offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides bmiMD offers
bmiMD sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.
Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.
Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.
Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.
Check the price yourself before you pay
Every figure here was read off bmiMD's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What bmiMD charges
The standing price at bmiMD is $99/month, unchanged as the dose goes up. That sits at the affordable end of what we track. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $99/month
- Compounded tirzepatide — $139/month
- Compounded semaglutide — $99/month
- Compounded tirzepatide — $139/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so bmiMD is genuinely under the middle rather than merely advertising that it is.
TRYM Health dispenses semaglutide and tirzepatide from $96/month, which makes it the honest comparison to run before committing here.
What bmiMD dispenses
bmiMD prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- you need access regardless of where you live
Our read
bmiMD competes on price and does it without an obvious sacrifice elsewhere: $99/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
bmiMD's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay bmiMD
Starting at $99/month. Check today's price, then book the free consultation.
Where bmiMD is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this bmiMD review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See bmiMD's current pricing
Plans start at $99/month. The free consultation is where you learn whether you qualify, and what it costs today.